Trospium
- Generic Name
- Trospium
- Brand Names
- Trosec
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30NO3
- CAS Number
- 47608-32-2
- Unique Ingredient Identifier
- T4Y8ORK057
- Background
Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by Indevus Pharmaceutical Inc. and was granted FDA approval in 2007.
- Indication
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.
- Associated Conditions
- Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
Phase 4
Completed
- Conditions
- PharmacokineticsElderlyOveractive Bladder
- Interventions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 12
- Registration Number
- NCT00863551
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath